Lenka Pulkrabkova

Hradec Kralove, KR 50005, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition.

Carltonine B derivatives: Synthesis and structure-activity relationship insights for selective butyrylcholinesterase inhibition.

Journal: Bioorganic chemistry

Published: February 11, 2026

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 08, 2025

Corrigendum to "Synthesis and broad-spectrum biocidal effect of novel gemini quaternary ammonium compounds" [Bioorg Chem. 151 (2024) 107646].

Corrigendum to "Synthesis and broad-spectrum biocidal effect of novel gemini quaternary ammonium compounds" [Bioorg Chem. 151 (2024) 107646].

Journal: Bioorganic chemistry

Published: September 29, 2024

Synthesis and broad-spectrum biocidal effect of novel gemini quaternary ammonium compounds.

Synthesis and broad-spectrum biocidal effect of novel gemini quaternary ammonium compounds.

Journal: Bioorganic chemistry

Published: May 07, 2024

Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.

Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.

Journal: RSC medicinal chemistry

Published: January 23, 2024

Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease.

Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 27, 2023

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease.

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease.

Journal: International journal of molecular sciences

Published: May 08, 2023

Differentiated SH-SY5Y neuroblastoma cells as a model for evaluation of nerve agent-associated neurotoxicity.

Differentiated SH-SY5Y neuroblastoma cells as a model for evaluation of nerve agent-associated neurotoxicity.

Journal: Archives of toxicology

Published: March 13, 2023

Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.

Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry

Published: February 13, 2023

Neurotoxicity evoked by organophosphates and available countermeasures.

Neurotoxicity evoked by organophosphates and available countermeasures.

Journal: Archives of toxicology

Published: June 30, 2022

N-substituted arylhydroxamic acids as acetylcholinesterase reactivators.

N-substituted arylhydroxamic acids as acetylcholinesterase reactivators.

Journal: Chemico-biological interactions

Published: June 26, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026